EP Patent

EP2134702B2 — Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals

Assigned to Pfizer Products Inc · Expires 2023-08-30 · 3y expired

What this patent protects

Patent listed against Inlyta.

Drugs covered by this patent

Patent Metadata

Patent number
EP2134702B2
Jurisdiction
EP
Classification
—
Expires
2023-08-30
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Products Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.